| -174G/C IL-6 gene promoter polymorphism predicts therapeutic response to TNF-α blockers. | |
| | |
MedLine Citation:
|
PMID: 22158445 Owner: NLM Status: Publisher |
Abstract/OtherAbstract:
|
BACKGROUND: Although TNF-α blockade is a very effective therapy for psoriasis, not all patients achieve a favorable outcome. The association between IL-6 and psoriasis has been investigated but no papers have focused on the pharmacogenetics of IL-6. OBJECTIVE: To examine whether the G or the C allele, at position -174 in the promoter of IL-6, influences the relationships between body weight, body composition, and therapeutic response to TNF-α blockers in psoriasis. METHODS: Sixty patients with psoriasis were studied, at baseline and 6-month follow-up after therapy. Assessment of the -174G/C IL-6 polymorphism, Psoriasis Area and Severity Index and Disease Activity Score-28 scores, body weight (kg), BMI, body composition by Dual-energy X-ray absorptiometry, and systemic inflammation was performed. RESULTS: Relevant body composition changes occurred after therapy. Normal weight participants showed a greater increase in fat mass than lean mass, compared with obese participants. According to their genotypes, C(+) carriers showed a greater increase in lean mass and fat mass, at the abdominal region, with respect to C(-) carriers. C(+) carriers outweighed C(-) carriers in the group of treatment responders. A higher number of responders were present among normal weight participants, with respect to obese participants. Obesity and the -174G/C IL-6 polymorphism predicted poor response to TNF-α blockers [odds ratio for C(-) carriers, obese: 2.00 (confidence interval: 1.19-3.38; P≤0.05)]. CONCLUSION: Our data show that the G allele of the -174G/C IL-6 polymorphism and obesity can be considered as risk factors for the prognosis and management of psoriasis. This is the first study to suggest the -174G/C IL-6 polymorphism as a novel genetic marker of responsiveness to TNF-α blockers in psoriasis. |
| | |
Authors:
|
Laura Di Renzo; Alessia Bianchi; Rosita Saraceno; Vittorio Calabrese; Caroline Cornelius; Leonardo Iacopino; Sergio Chimenti; Antonino De Lorenzo |
Related Documents
:
|
17133645 - Learning from directed evolution: further lessons from theoretical investigations into ... 22157285 - The genetics of cancer risk. 21940615 - Infantile convulsions and paroxysmal kinesigenic dyskinesia with 16p11.2 microdeletion. 21647605 - Association mapping of dynamic developmental plant height in common wheat. 20046055 - Association of the g2014g genotype in estrogen receptor 1 gene with failure of the mife... 12325025 - Ptpn11 mutations in noonan syndrome type i: detection of recurrent mutations in exons 3... |
Publication Detail:
|
Type: JOURNAL ARTICLE Date: 2011-12-12 |
Journal Detail:
|
Title: Pharmacogenetics and genomics Volume: - ISSN: 1744-6880 ISO Abbreviation: - Publication Date: 2011 Dec |
Date Detail:
|
Created Date: 2011-12-13 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 101231005 Medline TA: Pharmacogenet Genomics Country: - |
Other Details:
|
Languages: ENG Pagination: - Citation Subset: - |
Affiliation:
|
aDepartment of Neuroscience, Division of Human Nutrition, University of Rome Tor Vergata bI.N.Di.M., National Institute for Mediterranean Diet and Nutrigenomic, Reggio Calabria cDepartment of Dermatology, University of Rome Tor Vergata-PTV, Italy. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Competitive and cooperative metabolic interactions in bacterial communities.
Next Document: Association of the GGCX (CAA)16/17 repeat polymorphism with higher warfarin dose requirements in Afr...